PTH and hypercalcemia disease: For this case, the patient developed severe hypercalcemia following denosumab cessation, with laboratory findings of suppressed PTH, normal PTHrP, and normal vitamin D, effectively ruling out primary hyperparathyroidism, humoral hypercalcemia, and vitamin D toxicity as primary etiologies.